Here, we have used glucagon-like peptide-1 (GLP-1) as a model peptide therapeutic for treating obesity-linked type 2 diabetes, a common chronic disease
There are ongoing legal proceedings and consolidated cases involving certain GLP1 medications, and the landscape continues to develop
Given that retatrutide is not currently licensed in the UK, the circumstances under which a patient might legitimately encounter this compound are limited primarily through participation in an approved clinical trial
Morales says that sometimes people accuse her of only promoting products, including the patches, to make money
PARP inhibition: PARP1 and beyond
Current guidance suggests using a barrier method, such as condoms, for at least four weeks after starting Mounjaro and for four weeks after each dose increase